MedTrace Logo

Prostate Specific Membrane Antigen PET/CT Imaging in PSMA-Related Disease Patients

NCT06690970 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2025-08-11

No results posted yet for this study

Summary

To evaluate the potential usefulness of 68Ga/18F-PSMA/PSFA positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various PSMA-related disease patients.

Conditions

Interventions

DIAGNOSTIC_TEST

68Ga/18F-PSMA/PSFA

Each subject receive a single intravenous injection of 68Ga/18F-PSMA/PSFA, and undergo PET/CT imaging within the specificed time.

Sponsors & Collaborators

  • Tianjin Medical University General Hospital

    collaborator OTHER

  • Tianjin Medical University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-09-01
Primary Completion
2027-12-01
Completion
2027-12-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06690970 on ClinicalTrials.gov